Approximately half of the funds awarded for Individual Investigator Research Awards (IIRA) went to MD Anderson faculty as well as 40% of total IIRA awards that include those for children’s and adolescent cancer and early detection and prevention.
The CPRIT awards will go toward studies in the areas of breast, skin, prostate, pancreas, colon and lung cancers in adults; leukemia and brain cancer in children; and for studies aimed at preventing colon cancer and lung cancer.
$16 million for Individual Investigator Research Awards (IIRA)
$3.8 million for Children and Adolescents
$2.5 million for Prevention and Early Detection.
A full listing of individual awards can be found below.
In addition, Immatics Biotechnologies was one of four Company Formation Awards funded by CPRIT. At more than $19 million, the project will further enable translation of immunotherapy knowledge from MD Anderson into new therapeutics for cancer patients.
“This is an astounding accomplishment and we’re extremely pleased that CPRIT has again recognized the significant scientific contributions being made by our world-class researchers,” said MD Anderson President Ronald DePinho, M.D. “I could not be more proud of the work that occurs every day at this institution and I commend those investigators who were awarded funding this week by CPRIT, as well as all the scientists and clinicians whose daily goal is no less than to end cancer.”
In 2014, MD Anderson received more than $47 million from CPRIT for research, prevention, recruitment and training. In total, the institution has received more than $215 million from CPRIT since its formation in 2009.
In November, CPRIT adopted new annual priorities to guide its grant awards, and specified that 10 of the awards would focus on childhood and adolescent and cancer, and five would address prevention and early detection of cancer. MD Anderson was awarded two grants in each of these new categories totaling more than $6.3 million.
MD Anderson IIRA-funded studies include the following:
Exploring Molecular and Immune Mechanisms of Response and Resistance to Combined BRAF/MEK Inhibition in Patients with High-Risk Resectable Metastatic Melanoma — $900,000
Elucidating the Evolution of the Premalignant Airway Genome in Space and Time — $886,173
Role of PTEN Feedback Mechanism in Cancer — $900,000
Targeting 17q23 Amplicon in HER2-Positive Breast Cancer — $828,242
Investigating the Regulation of miRNA and IncRNAs by p63 in Mammary Tumor Progression and Metastasis — $900,000
Genome Stability and Immune Diversity Controlled by the POLQ Pathway — $900,000
Identifying Drivers of Lung Metastasis in Triple Negative Breast Cancer — $899,637
Regulation of Dormancy of Metastatic Prostate Cancer Cells by Bone Microenvironment — $900,000
Discovering the Molecular Mechanisms that Determine Replicative Lifespan — $892,104
Function of Fibroblasts and Collagen I in Pancreas Cancer — $898,811
Role of TBK1 in Regulating Dendritic Cell Function and Antitumor Immunity — $876,958
EGFR Arginine Methylations: Biomarkers for Cetuximab Resistance in Colon Cancer — $900,000
Mechanisms of De Novo and Acquired Resistance to Therapeutic Treatment of Bone-Metastatic Prostate Cancer — $900,000
Identification of Clinically Relevant Targets for Radiosensitization — $899,280
T-Cell Activating Immunotherapy for Indolent B-Cell Malignancies — $852,595
Leukemia Inhibitory Factor Receptor Signaling and Function in Cancer — $900,000
On the Role of DEAR1 in the Regulation of Cell Polarity and Progression from DCIS to Invasive Breast Cancer — $899,846
Tumor Cell Epithelial-Mesenchymal Transition in Regulating Immunosuppression and Metastasis in Lung Cancer — $900,000
IIRA-funded studies for Cancer in Children and Adolescents at MD Anderson included:
Defining and Treating Targetable Lesions in AYA Acute Lymphoblastic Leukemia — $1,989,950
Epigenetics in Medulloblastoma Development and Therapeutics — $1,871,708
MD Anderson also was awarded the following IIRA-funded studies for Prevention and Early Detection included:
Mechanisms of DHA and EPA Differential Effects on Colon Cancer Chemoprevention — $920,926
Varenicline and Combined NRT for Initial Smoking Cessation and Rescue Treatment in Smokers: A Randomized Pilot Trial — $1,493,464
CPRIT has awarded more than $1 billion in grants to Texas researchers, institutions, nonprofits and private enterprises. It provides funding through its research, scientific and product development and prevention programs. Programs made possible with CPRIT funding have reached every corner of the state, brought more than 80 distinguished researchers to Texas, advanced scientific and clinical knowledge, and provided more than 1.9 million life-saving education, training, prevention and early detection services to Texans.